MNKD July 19th Options Begin Trading

Investors in MannKind Corp ( MNKD) saw new options become available today, for the July 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 102 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

The put contract at the $6.00 strike price has a current bid of $1.32. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $6.00, but will also collect the premium, putting the cost basis of the shares at $4.68 (before broker commissions). To an investor already interested in purchasing shares of MNKD, that could represent an attractive alternative to paying $6.33/share today.

Because the $6.00 strike represents an approximate 5% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 66%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 22.00% return on the cash commitment, or 78.73% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Below is a chart showing the trailing twelve month trading history for MannKind Corp, and highlighting in green where the $6.00 strike is located relative to that history:

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind